CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB019

Thyroid Disease Testing

Criteria and reimbursement guidance for laboratory testing of thyroid disease for BCBS Oklahoma members, describing when specific thyroid function and antibody tests are reimbursable and when certain tests are not covered.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyThyroid Disease Testing

Policy CodePolicy CPCPLAB019

Change TypeNo material change

Effective DateNov 1, 2022

Next Review Date

Key ActionProviders must submit accurate documentation and verify plan-specific eligibility; check member plan documents for prior authorization requirements.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1.0policy version

11/01/2022effective / update

16+covered scenarios

15+references

Coverage Criteria for Thyroid Testing

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Hypothyroidism evaluation and monitoring: TSH to confirm or rule out primary hypothyroidism; free T4 as a follow-up to abnormal TSH findings or when secondary hypothyroidism is suspected; TSH to distinguish between primary and secondary hypothyroidism; TSH and free T4 for monitoring individuals treated for hypothyroidism every 6-12 weeks after a dosage change and annually when stable.

Hyperthyroidism evaluation and monitoring: TSH to confirm or rule out primary hyperthyroidism; free T4 as a follow-up to abnormal TSH; total or free T3 as a follow-up to abnormal FT4 findings or if clinical concern persists; free T4 to distinguish between primary and secondary hyperthyroidism; TSH and free T4 for monitoring individuals treated for hyperthyroidism every 6-12 weeks, with close monitoring in the first 3 months after treatment and annual monitoring thereafter.

Asymptomatic high-risk individuals: One-time TSH testing for individuals with a personal or family history of thyroid dysfunction or type 1 diabetes/other autoimmune disorder; annual TSH testing for individuals prescribed drugs that can interfere with thyroid function or when dosage/medication changes occur (examples include amiodarone, interferon, iodine, lithium, tyrosine kinase inhibitors, sulfonamides).

Reproductive and pregnancy-related indications: Testing for women undergoing infertility evaluation; pregnant and postpartum women per pregnancy-specific guidance including: monitoring pregnant women being treated for hypothyroidism every 4 weeks; free T4 or total T4 testing for management of thyroid disease during pregnancy (see Note 1); FT4 measurement in the first trimester when serum TSH is suppressed; measurement of serum total T3 and thyrotropin receptor antibodies (TRAb) when establishing a diagnosis of hyperthyroidism; TSH testing for thyroid nodules; TSH to evaluate hypothyroidism in the first trimester and in the postpartum period.

Specific clinical conditions: Testing for patients with disease or neoplasm of the thyroid or other endocrine glands; individuals with chronic or acute urticaria; individuals undergoing immune reconstitution therapy; patients with relapsing-remitting MS treated with alemtuzumab; individuals with HIV on HAART; individuals following allogeneic BMT/HSCT; individuals suspected of central hypothyroidism; pediatric patients with short stature.

Thyroid antibody and tumor marker testing: Testing for thyroid antibodies for evaluation of autoimmune thyroiditis; serum thyroglobulin and anti-thyroglobulin antibody testing for detection of tumor recurrence, postsurgical evaluation, surveillance, and maintenance in differentiated thyroid carcinomas.

TRH testing: Testing for thyrotropin-releasing hormone (TRH) may be reimbursable for evaluation of the cause of hyperthyroidism or hypothyroidism.

inv-02: Not medically necessary / not reimbursable

Not reimbursable except as noted:

Tests not reimbursable: Reverse T3, T3 uptake, and total T4 testing are not reimbursable in all situations except total T4 testing for management of thyroid disease during pregnancy (see Note 1). Measurement of total T3 and/or free T3 is not reimbursable in the assessment of hypothyroidism. Measurement of total or free T3 level is not reimbursable when assessing levothyroxine dose in hypothyroid patients.

Screening not reimbursable: Testing for thyroid dysfunction in asymptomatic nonpregnant individuals during general examinations without abnormal findings is not reimbursable.

Specific Covered Indications

inv-12: Individuals with symptoms consistent with hypothyroidism

Initial diagnostic testing: Obtain serum TSH to confirm or rule out primary hypothyroidism in individuals with symptoms consistent with hypothyroidism.

Follow-up testing: If TSH is abnormal or secondary hypothyroidism is suspected (normal TSH with clinical concern), obtain free T4 as a follow-up to assess free hormone status.

Distinguishing primary vs secondary: Use TSH (with free T4 if needed) to distinguish primary from secondary hypothyroidism.

Monitoring after treatment change: For individuals being treated for hypothyroidism, measure TSH and free T4 every 6-12 weeks after a dosage change.

Long-term monitoring: For individuals with stable hypothyroidism on therapy, measure TSH and free T4 annually.

inv-13: Individuals with symptoms consistent with hyperthyroidism

Initial diagnostic testing: Obtain serum TSH to confirm or rule out primary hyperthyroidism in individuals with symptoms consistent with hyperthyroidism.

Follow-up testing: If TSH is abnormal, obtain free T4 as a follow-up; obtain total or free T3 if FT4 is abnormal or clinical concern for persistent hyperthyroidism remains.

Distinguishing primary vs secondary: Use free T4 to help distinguish between primary and secondary hyperthyroidism when clinically indicated.

Monitoring after treatment: Measure TSH and free T4 for monitoring individuals treated for hyperthyroidism every 6-12 weeks after treatment; closely monitor during the first 3 months post-treatment and perform annual monitoring thereafter due to risk of relapse or late-onset hypothyroidism.

inv-14: Pregnancy, infertility, postpartum, and high-risk asymptomatic individuals

Infertility evaluation: TSH testing for women undergoing evaluation for infertility.

Pregnancy monitoring when treated for hypothyroidism: Monitor pregnant women being treated for hypothyroidism with TSH testing every 4 weeks.

Pregnancy-specific hormone testing: Free T4 is preferred for pregnancy management; total T4 (TT4) is allowed when FT4 reference ranges are unavailable or results are discordant (see Note 1). FT4 should be measured in the first trimester when serum TSH is suppressed.

Postpartum and nodule evaluation: TSH testing to evaluate hypothyroidism in the first trimester and in the postpartum period; TSH testing if a thyroid nodule is present.

inv-15: Thyroid cancer surveillance

Surveillance tumor markers: Measure serum thyroglobulin and anti-thyroglobulin antibody levels for detection of tumor recurrence, postsurgical evaluation, surveillance, and maintenance in individuals with differentiated thyroid carcinomas.

Antibody testing for autoimmune evaluation: Thyroid antibody testing may be reimbursable for evaluation of autoimmune thyroiditis in appropriate clinical contexts.

Testing Frequency and Monitoring

TSH and free T4 monitoring — treated hypothyroidism/hyperthyroidism

TestsTSH and free T4 for monitoring individuals treated for hypothyroidism or hyperthyroidism

Frequency after dose changeEvery 6–12 weeks

Frequency when stableAnnually

TSH and free T4 — post-hyperthyroidism treatment monitoring

TestsTSH and free T4 for individuals treated for hyperthyroidism

Immediate post-treatment monitoringClose monitoring during the first 3 months after treatment

Long-term monitoringAnnual monitoring after the first year even if asymptomatic

TSH monitoring in pregnancy (treated hypothyroidism)

TestTSH for pregnant women being treated for hypothyroidism

FrequencyEvery 4 weeks during pregnancy

PurposeMonitor and adjust therapy to maintain pregnancy-appropriate thyroid levels

TSH — one-time testing for asymptomatic high-risk individuals

TestOne-time TSH testing for asymptomatic high-risk individuals

Eligible high-risk groupsPersonal or family history of thyroid dysfunction; personal or family history of type 1 diabetes or other autoimmune disorder

LimitTesting for these high-risk asymptomatic individuals is limited to one time

TSH — annual testing for drug-related thyroid interference or medication changes

TestAnnual TSH testing for individuals on drugs that interfere with thyroid function

Also applicableWhen medication or dose changes occur (test at time of change)

Examples of interfering drugsAmiodarone, interferon, iodine, lithium, tyrosine kinase inhibitors, sulfonamides (not an exhaustive list)

Not Covered Tests and Limitations

Reverse T3, T3 uptake, and total T4 testing are not covered in virtually all situations except that total T4 (TT4) may be reimbursable for managing thyroid disease during pregnancy. For pregnancy testing, laboratories must use trimester-specific reference ranges for the assay. Note that FT4 is the preferred pregnancy test, and TT4 is acceptable when FT4 reference ranges are unavailable or when TSH and FT4 are discordant. Additionally, measurement of total or free T3 is not reimbursable for assessment of hypothyroidism or for guiding levothyroxine dosing in hypothyroid patients.

Provider Actions and Billing Guidance

Prior Authorization

Plan-specific prior authorization and coverage

Not all prior-authorization or lab management requirements apply to every BCBS OK product. Providers should review the member's plan documents (Certificate of Benefits, Summary Plan Description, benefit booklet, or other coverage documents) to determine eligibility and any prior authorization requirements before ordering tests.

Plan documents govern coverage and may supersede this policy.
BCBS OK may apply discretion when interpreting and applying policy to a specific case.

Documentation Required

General provider responsibilities

Providers are responsible for submitting accurate documentation of services performed and for using valid HIPAA-approved code sets when submitting claims. Claims must be coded according to standard industry guidelines.

Use HIPAA-approved code sets (CPT, HCPCS, ICD-10, NDC, DRG) and follow AMA/CPT, CMS NCCI/CCI, and other applicable coding guidance.
Be prepared to provide additional documentation upon request to support medical necessity and billing.
If a conflict exists between this Clinical Payment and Coding Policy and a provider contract or plan document, the provider contract or plan document will govern.

Denial Risk

Claims submission and denial risk

Claims for laboratory testing are subject to code-edit protocols and medical policy review; improper or non-covered testing may be denied. Testing during a general exam without abnormal findings in asymptomatic nonpregnant individuals is not reimbursable.

Providers must submit claims using appropriate CPT/HCPCS codes and modifiers where applicable.
Claims are subject to benefit, contract, and policy review and to coding software logic and edits.
Testing for thyroid dysfunction in asymptomatic nonpregnant individuals during a general exam without abnormal findings is not reimbursable.

Billing Rule

Specific testing reimbursement and documentation

Certain thyroid and related tests are reimbursable only for specified clinical indications; providers should document the clinical rationale and ensure lab assays (e.g., FT4 during pregnancy) have appropriate trimester-specific reference ranges when required.

Reimbursable indications include, but are not limited to: management of individuals on alemtuzumab, individuals with HIV on HAART, post-allogeneic BMT/HSCT, suspected central hypothyroidism, and pediatric short stature evaluation.
Thyroid antibody testing may be reimbursable for evaluation of autoimmune thyroiditis.
Serum thyroglobulin and anti-thyroglobulin antibody testing may be reimbursable for surveillance of differentiated thyroid carcinoma.
TRH testing may be reimbursable to evaluate causes of hyper- or hypothyroidism.
Reverse T3, T3 uptake and total T4 are generally not reimbursable except total T4 may be reimbursable for management during pregnancy when trimester-specific TT4 interpretation is appropriate.
Measurement of total T3 and/or free T3 is not reimbursable for assessment of hypothyroidism or for adjusting levothyroxine dose.

Ordering and Administrative Requirements

Billing Rule

Ordering and claim submission requirements

Confirm member eligibility and plan-specific coverage before ordering; submit claims with valid, appropriately selected codes and supporting documentation as described in plan documents and coding guidance.

Check the member's plan documents for specific coverage applicability and any ordering restrictions.
Use HIPAA-approved code sets and follow industry coding guidelines when submitting claims.

Background

Thyroid function testing is used to diagnose and monitor hypothyroidism and hyperthyroidism and to manage thyroid disease in special situations such as pregnancy, infertility, post-treatment surveillance, and certain high-risk conditions. TSH is the primary test for initial evaluation and screening; free T4 (FT4) and T3 measurements are used as follow-up or in specific clinical settings. During pregnancy, physiologic changes in thyroid hormones require trimester-specific reference ranges, and FT4 is preferred; TT4 may be used when FT4 ranges are not available or when results are discordant. Several other tests (thyroid antibodies, thyroglobulin) may be reimbursable when clinically indicated, while tests such as reverse T3, T3 uptake, and routine TT4 outside pregnancy are generally not reimbursable.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyThyroid Disease Testing

Policy CodePolicy CPCPLAB019

Change TypeNo material change

Effective DateNov 1, 2022

Next Review Date

Key ActionProviders must submit accurate documentation and verify plan-specific eligibility; check member plan documents for prior authorization requirements.

SourceLink

On This Page

80438
80439
83519
84432
84436
84437
84439
84442
84443
84445

OpenPayer

Thyroid Disease Testing

Coverage Criteria for Thyroid Testing

Specific Covered Indications

Testing Frequency and Monitoring

Not Covered Tests and Limitations

Listed Codes

Provider Actions and Billing Guidance

Ordering and Administrative Requirements

Background

Definitions and Notes